BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...$48.7 million) in a private placement through the sale of 13.3 million shares at NOK37.50. GSR...
...Limbix Digital therapeutics play Limbix raised $9 million in a series A round led by GSR...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...$25 million in an offering, bringing its total funds raised to more than $45 million. GSR...
BioCentury | Jan 31, 2018
Distillery Techniques

Biomarkers

...Gut microbiota counts of Prevotella and Bacteroides species could help predict responses to acarbose or glipizide...
...of fecal samples from 51 patients treated with acarbose and another 43 patients treated with glipizide...
...include confirming the findings in larger cohorts of Type II diabetes patients. The generic sulfonylurea glipizide...
BioCentury | May 26, 2014
Clinical News

Xigduo dapagliflozin/metformin regulatory update

...or other blood-glucose lowering drugs. IQWiG said in a study that compared Xigduo monotherapy to glipizide...
BioCentury | Jul 15, 2013
Clinical News

Januvia sitagliptin regulatory update

...goal. IQWiG also said that Januvia plus metformin has "major" additional benefit over the sulfonylurea glipizide...
...sugar level is the therapeutic goal, while the combination has an "unquantifiable" additional benefit over glipizide...
...plus metformin, 1 man died in the Januvia arm, while 8 men died in the glipizide...
BioCentury | Mar 18, 2013
Clinical News

Dapagliflozin regulatory update

...comparing Forxiga plus metformin vs. sulfonylurea plus metformin were not suitable because the sulfonylurea used, glipizide...
...not been marketed in Germany since 2007. The institute said the partners failed to show glipizide...
BioCentury | Mar 18, 2013
Regulation

Disarmamentarium in Germany

...intolerant to metformin. For Forxiga plus metformin, IQWiG said the company used the wrong sulfonylurea, glipizide...
...or glibenclamide. The same rationale was used for the Forxiga combination with glipizide. IQWiG argued glipizide...
...in IQWiG's preliminary benefit assessment in February because the trial submitted for dual therapy used glipizide...
BioCentury | Mar 15, 2013
Top Story

IQWiG rebuffs Forxiga

...comparing Forxiga plus metformin vs. sulfonylurea plus metformin were not suitable because the sulfonylurea used, glipizide...
...not been marketed in Germany since 2007. The institute said the partners failed to show glipizide...
BioCentury | Feb 18, 2013
Clinical News

Komboglyze saxagliptin/metformin regulatory update

...institute said the data AstraZeneca submitted were not suitable because the pharma compared Komboglyze with glipizide...
...not been marketed in Germany since 2007. IQWiG said AstraZeneca also failed to show that glipizide...
...comparators by Germany's Federal Joint Committee (G-BA). AstraZeneca said it believes it showed equivalence of glipizide...
BioCentury | Feb 16, 2013
Company News

Germany says Komboglyze has 'no additional benefit'

...institute said the data AstraZeneca submitted were not suitable because the pharma compared Komboglyze with glipizide...
...has not been marketed in Germany since 2007. IQWiG said AstraZeneca failed to show that glipizide...
Items per page:
1 - 10 of 29